Who
Hilde Johanna van der Kamp
Director
Company insider
Files Form 4 as: Director, NewAmsterdam Pharma Company.
In numbers
- Trades disclosed
- 7
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 1 Jan 2024
- Last trade
- 7 Jan 2026
- Last filed
- 9 Jan 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Jan 2026filed 9 Jan 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Code A | —3,400 | filing |
| 7 Jan 2026filed 9 Jan 2026 | NAMS NewAmsterdam Pharma Companyoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,300 at $0.00 | filing |
| 7 Jan 2026filed 9 Jan 2026 | NAMS NewAmsterdam Pharma Companyoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,300 at $0.00 | filing |
| 7 Jan 2026filed 9 Jan 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Code A | —3,400 | filing |
| 7 Jan 2025filed 8 Jan 2025 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Code A | —6,960 | filing |
| 6 Jan 2025filed 8 Jan 2025 | NAMS NewAmsterdam Pharma Companyoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,500 at $0.00 | filing |
| 1 Jan 2024filed 3 Jan 2024 | NAMS NewAmsterdam Pharma Companyoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.